NEW YORK — Finnish infectious disease testing firm ArcDia International said on Thursday that it has signed a Central European distribution deal for its automated MariPOC point-of-care testing platform and related infectious diseases immunoassays with Hain Lifescience.
MariPOC uses two-photon excitation technology for the rapid multianalyte identification of pathogenic antigens, as well as the detection of inflammation biomarkers and antimicrobial resistance. ArcDia offers a range of tests that run on the system including ones for tonsillitis and throat infections, acute gastrointestinal infections, and respiratory infections caused by influenza and SARS-CoV-2.
Under the terms of the deal, Hain will exclusively distribute the MariPOC product line in Germany, Austria, Switzerland, Belgium, the Netherlands, and Luxembourg. Hain, a German subsidiary of Bruker, will nonexclusively distribute the products in certain other European markets.
Additional terms were not disclosed.
In early 2019, ArcDia signed an exclusive licensing deal for its biochemical assay components in China with Xinhua Healthcare Industry.